Key players in the global overactive bladder treatment (OAB) market include Astellas Pharma Inc. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (US), Medtronic Plc (Ireland) In March 2021, Myrbetriq received the U.S. Food and Drug Administration approval to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three […]
